S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)

AbbVie Stock Forecast, Price & News

$131.98
-1.05 (-0.79%)
(As of 01/21/2022 12:00 AM ET)
Add
Compare
Today's Range
$131.67
$134.25
50-Day Range
$115.28
$137.29
52-Week Range
$101.81
$138.15
Volume
7.45 million shs
Average Volume
7.81 million shs
Market Capitalization
$233.23 billion
P/E Ratio
31.42
Dividend Yield
4.24%
Beta
0.86
30 days | 90 days | 365 days | Advanced Chart
Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.


AbbVie logo

About AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
00287Y10
Employees
47,000
Year Founded
2013

Sales & Book Value

Annual Sales
$45.80 billion
Cash Flow
$13.25 per share
Book Value
$7.42 per share

Profitability

Net Income
$4.62 billion
Pretax Margin
13.07%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares
1,767,176,000
Free Float
1,765,586,000
Market Cap
$233.23 billion
Optionable
Optionable

Company Calendar

Ex-Dividend for 11/15 Dividend
10/14/2021
Last Earnings
10/28/2021
Dividend Payable
11/15/2021
Ex-Dividend for 2/15 Dividend
1/13/2022
Today
1/21/2022
Next Earnings (Confirmed)
2/02/2022
Dividend Payable
2/15/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

3.06 out of 5 stars

Medical Sector

17th out of 1,418 stocks

Pharmaceutical Preparations Industry

4th out of 683 stocks

Analyst Opinion: 2.4Community Rank: 4.9Dividend Strength: 4.2Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -












AbbVie (NYSE:ABBV) Frequently Asked Questions

Is AbbVie a buy right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last twelve months. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AbbVie stock.
View analyst ratings for AbbVie
or view top-rated stocks.

How has AbbVie's stock been impacted by Coronavirus?

AbbVie's stock was trading at $84.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ABBV shares have increased by 55.5% and is now trading at $131.98.
View which stocks have been most impacted by COVID-19
.

When is AbbVie's next earnings date?

AbbVie is scheduled to release its next quarterly earnings announcement on Wednesday, February 2nd 2022.
View our earnings forecast for AbbVie
.

How can I listen to AbbVie's earnings call?

AbbVie will be holding an earnings conference call on Wednesday, February 2nd at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) issued its quarterly earnings data on Thursday, October, 28th. The company reported $3.33 EPS for the quarter, topping the Zacks' consensus estimate of $3.22 by $0.11. The firm earned $14.34 billion during the quarter, compared to analysts' expectations of $14.30 billion. AbbVie had a trailing twelve-month return on equity of 166.05% and a net margin of 13.66%. The company's revenue was up 11.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.83 EPS.
View AbbVie's earnings history
.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Friday, October 29th. Stockholders of record on Friday, January 14th will be paid a dividend of $1.41 per share on Tuesday, February 15th. This represents a $5.64 dividend on an annualized basis and a dividend yield of 4.27%. The ex-dividend date is Thursday, January 13th. This is a boost from AbbVie's previous quarterly dividend of $1.30.
View AbbVie's dividend history
.

Is AbbVie a good dividend stock?

AbbVie pays an annual dividend of $5.64 per share and currently has a dividend yield of 4.24%. ABBV has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. AbbVie has been increasing its dividend for 50 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of AbbVie is 134.29%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, AbbVie will have a dividend payout ratio of 40.03% next year. This indicates that AbbVie will be able to sustain or increase its dividend.
View AbbVie's dividend history.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its fourth quarter 2021 earnings guidance on Wednesday, November, 10th. The company provided earnings per share guidance of $3.240-$3.280 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.300. The company issued revenue guidance of $15 billion-$15 billion, compared to the consensus revenue estimate of $15.01 billion.

What price target have analysts set for ABBV?

15 equities research analysts have issued 1 year price objectives for AbbVie's stock. Their forecasts range from $113.00 to $165.00. On average, they anticipate AbbVie's stock price to reach $141.42 in the next year. This suggests a possible upside of 7.2% from the stock's current price.
View analysts' price targets for AbbVie
or view top-rated stocks among Wall Street analysts.

Who are AbbVie's key executives?

AbbVie's management team includes the following people:
  • Richard A. Gonzalez, Chairman & Chief Executive Officer (LinkedIn Profile)
  • Michael E. Severino, Vice Chairman-Management Board & President
  • Azita Saleki-Gerhardt, Executive Vice President-Operations
  • Robert A. Michael, CFO, Vice Chairman-Finance & Commercial Operations
  • Thomas J. Hudson, Chief Scientific Officer, Senior VP-R&D

What is Richard A. Gonzalez's approval rating as AbbVie's CEO?

580 employees have rated AbbVie CEO Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among AbbVie's employees.

What other stocks do shareholders of AbbVie own?

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

Who are AbbVie's major shareholders?

AbbVie's stock is owned by many different retail and institutional investors. Top institutional investors include Nordea Investment Management AB (0.22%), Retirement Systems of Alabama (0.07%), Russell Investments Group Ltd. (0.06%), Royal London Asset Management Ltd. (0.05%), Guinness Asset Management LTD (0.04%) and Donaldson Capital Management LLC (0.03%). Company insiders that own AbbVie stock include Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Edward J Rapp, Elaine K Sorg, Jeffrey Ryan Stewart, Laura J Schumacher, Richard A Gonzalez, Roxanne S Austin, Timothy J Richmond and Timothy J Richmond.
View institutional ownership trends for AbbVie
.

Which institutional investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., Moody National Bank Trust Division, Russell Investments Group Ltd., Royal London Asset Management Ltd., HBW Advisory Services LLC, Gateway Investment Advisers LLC, AAFMAA Wealth Management & Trust LLC, and Retirement Systems of Alabama. Company insiders that have sold AbbVie company stock in the last year include Brian L Durkin, Carrie C Strom, Elaine K Sorg, Jeffrey Ryan Stewart, Laura J Schumacher, Richard A Gonzalez, Roxanne S Austin, and Timothy J Richmond.
View insider buying and selling activity for AbbVie
or view top insider-selling stocks.

Which institutional investors are buying AbbVie stock?

ABBV stock was acquired by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, Sabal Trust CO, International Assets Investment Management LLC, Guinness Asset Management LTD, Asymmetry Capital Management L.P., Clear Street Markets LLC, Stonnington Group LLC, and Aries Wealth Management. Company insiders that have bought AbbVie stock in the last two years include Brian L Durkin, and Edward J Rapp.
View insider buying and selling activity for AbbVie
or or view top insider-buying stocks.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $131.98.

How much money does AbbVie make?

AbbVie has a market capitalization of $233.23 billion and generates $45.80 billion in revenue each year. The company earns $4.62 billion in net income (profit) each year or $4.20 on an earnings per share basis.

How many employees does AbbVie have?

AbbVie employs 47,000 workers across the globe.

Does AbbVie have any subsidiaries?

The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska družba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacéuticos S.A. de C.V., AbbVie Farmacêutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S.à r.l., AbbVie Investments Limited, AbbVie Investments S.à r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementär GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Ltd., AbbVie Overseas S.à r.l., AbbVie Oy, AbbVie Participações Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. z o.o., AbbVie Productos Farmacéuticos Limitada, AbbVie Products LLC, AbbVie Promoção L.da, AbbVie Pte. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S.à r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Bhd., AbbVie Sp. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundación AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC.

When was AbbVie founded?

AbbVie was founded in 2013.

What is AbbVie's official website?

The official website for AbbVie is www.abbvie.com.

Where are AbbVie's headquarters?

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049.


This page was last updated on 1/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.